Pharmaceutical - Inflammatory diseases


Current filters:

Inflammatory diseases

Popular Filters

51 to 55 of 55 results

BioLineRx inks deal with Compugen


Israeli biopharma company BioLineRx (TASE: BLRX) has entered into a collaboration with fellow Israel-based…

BioLineRxBiotechnologyCardio-vascularCompugenInflammatory diseasesLicensingOncologyPharmaceuticalResearch

New start-up TopiVert gets $12.5 million funding


UK investment group Imperial Innovations (AIM: IVO) and SV Life Sciences have committed to invest £8…

FinancialInflammatory diseasesJohnson & JohnsonPharmaceuticalResearchRespiVertTopiVert

Compugen links with DiscoveRx on novel peptide ligands for GPCR drug targets


Israel’s Compugen (Nasdaq: CGEN) and USA-based DiscoveRx have entered into a partnership for the…

Cardio-vascularCompugenDiscoveRxInflammatory diseasesPharmaceuticalResearch

Mundipharma commits over $50 million in R&D funding for Infinity’s PI3K inhibitor


Privately-held Mundipharma International as committed to providing over $50 million in funding in 2013…

FinancialInfinity PharmaceuticalsInflammatory diseasesLicensingMundi InternationalOncologyPharmaceuticalResearch

51 to 55 of 55 results

Back to top